U.K. PCI study sparks U.S. debate
On Wednesday, November 1, results from the Objective Randomized Blinded Investigation with Optimal Medical Therapy of Angioplasty in Stable Angina (ORBITA) study were published in The Lancet.
The next day, this article was published in the New York Times:
"A procedure used to relieve chest pain in hundreds of thousands of heart patients each year is useless for many of them," it began... "The new study, published in the Lancet, stunned leading cardiologists by countering decades of clinical experience. The findings raise questions about whether stents should be used so often—or at all—to treat chest pain."
Without further knowledge, the debate may start right here—the New York Times article had little in the way of medical detail to satisfy invasive cardiovascular professionals and may have further generalized results in a misleading manner.
But let's hold off on reacting, look at the debate surrounding this particular study and also place the findings in a wider context (part two). Note: this isn't the first time it has been suggested that stents are overused.
Continue reading Stents not effective? Study sparks debate pt. 1
Genetic arrhythmia programs are paving new roads for personalized cardiac care—from preventing unnecessary cautionary testing or treatment to improving screening.
Melvin Scheinman, MD—the first person to perform catheter ablation for arrhythmia in a human patient, now chief of the Comprehensive Genetic Arrhythmia Program at the University of California, San Francisco—believes genetic testing will lead to the "ultimate form of personalized medicine," writes Gregory A. Freeman of HealthLeaders Magazine.
"If you examine the genetic background of a patient, you may be able to identify sensitivity to specific drugs, propensity for developing some very serious heart disorders, and at the same time rule out those same things for other people," said Scheinman to HealthLeaders.
"That is really what personalized medicine is all about—delivering the right care to the patient because you truly understand the patient and don't have to treat him or her as just a member of a group with certain statistical risks."
A proliferation of genetic arrhythmia programs "across the country" have been introducing new, measured responses to a sudden cardiac death in the family—preventive healthcare for some, but not all family members.
Continue reading Future of cardiology: personalized care through genetics?
With a proliferation of guidelines designed to reduce costs based on the risk profiles of patients, and a more general trend towards a preventative care framework, it’s important to stay on top of the latest research into these risk factors for cardiovascular disease.
What constitutes a high-risk patient? What’s new in risk assessment? We've already discussed a new factor identified with a predictive value similar to cholesterol levels. Researchers have also found a gene that indicates high risk for heart disease in women.
Continue reading Cardiovascular Risk Report: New Genetic Risk in Women Identified
With a proliferation of guidelines designed to reduce costs based on the risk profiles of patients, and a more general trend towards a preventative care framework, it's important to stay on top of the latest research into these risk factors for cardiovascular disease.
What constitutes a high-risk patient? What's new in risk assessment? Stay tuned, ACVP blog will bring you more on the latest in cardiovascular disease risk factors.
"Stem Cell Factor" Linked to Cardiovascular Disease Risk
A new study published in the Journal of Internal Medicine identified a risk factor with a similar predictive value to established cardiovascular risk factors such as LDL and HDL cholesterol.
Continue reading Cardiovascular Risk Report: “Stem Cell Factor” as Predictive as Cholesterol Levels